Valneva SE (VALN) Current Deferred Revenue (2021 - 2025)
Valneva SE's (VALN) quarterly Current Deferred Revenue came in at $502866.8 in Q4 2025, down 84.37% year-on-year from $3.2 million in Q4 2024, and down 98.82% quarter-over-quarter from $42.5 million in Q2 2025.
Valneva SE (VALN) Current Deferred Revenue (2021 - 2025) Analysis & Trends
Valneva SE has disclosed Current Deferred Revenue across 5 years of filings, most recently posting $502866.8 for Q4 2025.
- Current Deferred Revenue for Q4 2025 came in at $502866.8, down 84.37% year-over-year; the trailing twelve-month figure through Dec 2025 was $502866.8 (down 84.37% YoY), and the FY2025 annual result was $502866.8, down 84.37% from the prior year.
- Current Deferred Revenue came in at $502866.8 for Q4 2025 at Valneva SE, down from $42.5 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $141.9 million in Q4 2021 to a low of $502866.8 in Q4 2025.
- The 5-year median for Current Deferred Revenue is $9.6 million (2022), against an average of $32.0 million.
- Across the five-year window, Current Deferred Revenue slumped 93.23% in 2022 and jumped 108.89% in 2025, its largest moves.
- Valneva SE's Current Deferred Revenue stood at $141.9 million in 2021, then plunged by 93.23% to $9.6 million in 2022, then sank by 36.16% to $6.1 million in 2023, then slumped by 47.53% to $3.2 million in 2024, then tumbled by 84.37% to $502866.8 in 2025.
- The last three Current Deferred Revenue figures came in at $502866.8 (Q4 2025), $42.5 million (Q2 2025), and $3.2 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 502,866.80 |
| Jun 30, 2025 | 42.51 Mn |
| Dec 31, 2024 | 3.22 Mn |
| Jun 30, 2024 | 20.35 Mn |
| Dec 31, 2023 | 6.13 Mn |
| Dec 31, 2022 | 9.60 Mn |
| Dec 31, 2021 | 141.87 Mn |